ライフサイエンスコーパス: guanylyl

1 -(beta,gamma)-imidotriphosphate) or GMP-PCP (guanylyl 5'-(beta,gamma)-methylenediphosphonate) nor GDP

2 ured by agonist-stimulated [(35)S]GTPgammaS (guanylyl-5'-[O-thio]-triphosphate) binding) in both cell

3 ave used the slowly-hydrolyzable GTP analog, guanylyl-(alpha,beta)-methylene-diphosphonate (GMPCPP),

4 structure for Cdc42 bound to the GTP analog guanylyl beta,gamma-methylene-diphosphonate (GMP-PCP) (i

5 UCY1A3 encodes the alpha1 subunit of soluble guanylyl cyclase (alpha1-sGC), and CCT7 encodes CCTeta,

6 ginine methyl ester) and blockade of soluble guanylyl cyclase (by ODQ; 1H-1,2,4-oxadiazolo[4,3-a]quin

7 PSM2), RAP1GAP, and Gbeta5; cGMP modulators: guanylyl cyclase (GC) 1alpha1, GC1beta1, phosphodiestera

8 hat is lost when the predicted PEPR receptor guanylyl cyclase (GC) active site is mutated.

9 pr1 promoter activity and greatly stimulated guanylyl cyclase (GC) activity of the receptor protein i

10 activation of the intestinal receptor-enzyme guanylyl cyclase (GC) C, triggers an acute, watery diarr

11 Phosphodiesterase (PDE) and guanylyl cyclase (GC) enzymes are key components of the

12 RhoGC is a rhodopsin (Rho)-guanylyl cyclase (GC) gene fusion molecule that is centr

13 Soluble guanylyl cyclase (GC) is a heterodimer that is activated

14 and MyD88-dependent recruitment of platelet guanylyl cyclase (GC) toward the plasma membrane, follow

15 eptides and ATP activate and Go6976 inhibits guanylyl cyclase (GC)-A and GC-B.

16 hosphorylation is required for activation of guanylyl cyclase (GC)-A, also known as NPR-A or NPR1, by

17 gical effects in cells largely by activating guanylyl cyclase (GC)-coupled receptors, leading to cGMP

18 of cGMP from its receptor, the NO-sensitive guanylyl cyclase (GC1).

19 MCs) by acting on its receptor, NO-sensitive guanylyl cyclase (NO-GC).

20 the application of a nitric oxide-sensitive guanylyl cyclase (NO-sGC) receptor antagonist, a NOS inh

21 tors from degeneration by preventing retinal guanylyl cyclase (RetGC) activation via calcium-sensing

22 Retinal membrane guanylyl cyclase (RetGC) and Ca(2+)/Mg(2+) sensor protei

23 hat change the Ca(2+) sensitivity of retinal guanylyl cyclase (retGC) can result from an increase in

24 al for normal expression of retinal membrane guanylyl cyclase (RetGC) in photoreceptor cells, blocks

25 (2+) sensor protein that accelerates retinal guanylyl cyclase (RetGC) in the light and decelerates it

26 ein, GCAP1, activates photoreceptor membrane guanylyl cyclase (RetGC) in the light, when free Ca(2+)

27 in promotes accumulation of retinal membrane guanylyl cyclase (RetGC) in the photoreceptor outer segm

28 oding for the dimeric human retinal membrane guanylyl cyclase (RetGC) isozyme RetGC1 cause various fo

29 depend on Ca(2+)-regulated retinal membrane guanylyl cyclase (RetGC), comprised of two isozymes, Ret

30 Retinal guanylyl cyclase (RetGC)-activating proteins (GCAPs) reg

31 hodiesterase (PDE6) or regulation of retinal guanylyl cyclase (retGC).

32 d Ca(2+) sensor in vision, regulates retinal guanylyl cyclase (RetGC).

33 calcium sensor proteins for retinal membrane guanylyl cyclase (RetGC).

34 The GUCY2D gene encodes retinal membrane guanylyl cyclase (RetGC1), a key component of the photot

35 utations in the AFD-expressed gcy-8 receptor guanylyl cyclase (rGC) gene result in defects in the exe

36 onstrate the effect of NO donors and soluble guanylyl cyclase (sGC) activators in differentiation of

37 tives have been studied as potential soluble guanylyl cyclase (sGC) activators.

38 Nitric oxide (NO) stimulates soluble guanylyl cyclase (sGC) activity, leading to elevated int

39 ivatives and tested their effects on soluble guanylyl cyclase (sGC) activity.

40 es that the functional properties of soluble guanylyl cyclase (sGC) are affected not only by the bind

41 dentified the alpha1-subunit gene of soluble guanylyl cyclase (sGC) as a novel androgen-regulated gen

42 nsertion is key during maturation of soluble guanylyl cyclase (sGC) because it enables sGC to recogni

43 es with the oxidation of the heme of soluble guanylyl cyclase (sGC) critically implicated in some of

44 nine (NMMA); 300 or 500 microM) or a soluble guanylyl cyclase (sGC) inhibitor (1H-[1,2,4]oxadiazolo[4

45 ell volume that was abolished by the soluble guanylyl cyclase (sGC) inhibitor 1H-[1,2,4]oxadiazolo[4,

46 -arginine methyl ester; 30 mg/kg), a soluble guanylyl cyclase (sGC) inhibitor [1H-(1, 2, 4) oxadiazol

47 either a nitric oxide scavenger or a soluble guanylyl cyclase (sGC) inhibitor diminished the benefici

48 The enzyme soluble guanylyl cyclase (sGC) is a heterodimer composed of an a

49 Soluble guanylyl cyclase (sGC) is a key component of NO-cGMP sig

50 Diatomic ligand discrimination by soluble guanylyl cyclase (sGC) is paramount to cardiovascular ho

51 Soluble guanylyl cyclase (sGC) is the main receptor for nitric o

52 Soluble guanylyl cyclase (sGC) is the principal receptor for NO

53 Soluble guanylyl cyclase (sGC) is the receptor for nitric oxide

54 MP levels in this pathway, including soluble guanylyl cyclase (sGC) itself, the NO -activated form of

55 and cGMP in the above effects using soluble guanylyl cyclase (sGC) or adenylate cyclase (AC) specifi

56 Soluble guanylyl cyclase (sGC) plays an important role in cardio

57 of the alpha1 and beta1 subunits of soluble guanylyl cyclase (sGC) was directly and specifically reg

58 d neuronal systems via activation of soluble guanylyl cyclase (sGC), a heme-containing heterodimer.

59 ch encodes the alpha1 subunit of the soluble guanylyl cyclase (sGC), a key enzyme in the nitric oxide

60 They were tested for activation of soluble guanylyl cyclase (sGC), a key enzyme in the NO/cGMP sign

61 Soluble guanylyl cyclase (sGC), a key protein in the NO/cGMP sig

62 nal nitric oxide synthase (nNOS) and soluble guanylyl cyclase (sGC), and can be mimicked by the nitri

63 otein complexes with NMDA receptors, soluble guanylyl cyclase (sGC), and PSD95.

64 the major downstream effector of NO, soluble guanylyl cyclase (sGC), is very limited.

65 through activation of its receptor, soluble guanylyl cyclase (sGC), leading to elevation of intracel

66 presence of inhibitors selective for soluble guanylyl cyclase (sGC), PKG, calmodulin, CaMKII or ERK1/

67 ural homology to the beta subunit of soluble guanylyl cyclase (sGC), suggesting a NO sensing function

68 homologous to the central region in soluble guanylyl cyclase (sGC), the main receptor for nitric oxi

69 ular mechanism of desensitization of soluble guanylyl cyclase (sGC), the NO receptor, has long remain

70 ly vasoactive through stimulation of soluble guanylyl cyclase (sGC), which produces the second messen

71 eased in cells that had a functional soluble guanylyl cyclase (sGC)-cGMP signaling pathway and was di

72 Nitric oxide (NO)-NO-sensitive (soluble) guanylyl cyclase (sGC)-cyclic guanosine monophosphate (c

73 renoceptors (beta(3)-ARs) coupled to soluble guanylyl cyclase (sGC)-dependent production of the secon

74 tivating its intracellular receptor, soluble guanylyl cyclase (sGC).

75 light source, to activate the enzyme soluble guanylyl cyclase (sGC).

76 We compared the NO/soluble guanylyl cyclase (sGC)/cGMP pathway in human glioma tiss

77 glutamate NMDA receptors (NMDA-Rs), soluble guanylyl cyclase (sGC, the NO receptor), and PSD95 (a pr

78 tes a pool of oxidized and heme-free soluble guanylyl cyclase (sGC; see the related article beginning

79 Although soluble guanylyl cyclase (which generates cyclic guanosine monop

80 s (GCAPs) bind and regulate retinal membrane guanylyl cyclase 1 (RetGC1) but not natriuretic peptide

81 erization domain of a human retinal membrane guanylyl cyclase 1 (RetGC1) linked to autosomal dominant

82 Retinal membrane guanylyl cyclase 1 (RetGC1) regulated by guanylyl cyclas

83 nfers Ca(2+)-sensitive activation of retinal guanylyl cyclase 1 (RetGC1).

84 Guanylyl cyclase 2C (GUCY2C) is a marker expressed by co

85 In intestinal epithelial cells, guanylyl cyclase 2C (GUCY2C) is a transmembrane receptor

86 o uroguanylin in the CNS, which can activate guanylyl cyclase 2C (GUCY2C) receptors in the brain to r

87 ic actions, as the endogenous ligand for the guanylyl cyclase 2C receptor has revealed a new system i

88 B-type natriuretic peptide (BNP) is a guanylyl cyclase A (GC-A) agonist.

89 effects were blocked by inhibition of either guanylyl cyclase A receptor or cyclic guanosine monophos

90 Endogenous pGC-A (particulate guanylyl cyclase A receptor) activators were reported to

91 Inhibition of the soluble guanylyl cyclase abolished the effect of L-arginine on g

92 Guanylyl cyclase activating protein 1 (GCAP-1), a Ca(2+)

93 Guanylyl cyclase activating protein 1 (GCAP1), a member

94 Guanylyl cyclase activating protein 1 (GCAP1), after sub

95 Two calcium-sensitive guanylyl cyclase activating proteins (GCAP1 and GCAP2) a

96 and cone photoreceptors by calcium-sensitive guanylyl cyclase activating proteins (GCAP1 and GCAP2) i

97 activity is modulated by the calcium-binding guanylyl cyclase activating proteins (GCAP1 and GCAP2).

98 etGC1 and RetGC2 isozymes using mice lacking guanylyl cyclase activating proteins GCAP1 and GCAP2 and

99 icial effects of both nitric oxide-sensitive guanylyl cyclase activation and inhibition of the cGMP-d

100 ing, leading to NO production and subsequent guanylyl cyclase activation and K(ATP) channel opening i

101 al NMDARs and NOS stimulation and subsequent guanylyl cyclase activation that probably occurred in pe

102 important role in NO generation and soluble guanylyl cyclase activation under hypoxic conditions, wi

103 With the addition of nitrite, soluble guanylyl cyclase activation was significantly higher in

104 n but are well-tuned to the dynamic range of guanylyl cyclase activation.

105 tors (VPAC2 and NPR-C), inhibit adenylyl and guanylyl cyclase activities, and stimulate cAMP-specific

106 uced dephosphorylation of NPR2 decreases its guanylyl cyclase activity in growth plate chondrocytes i

107 y changes, but the absence of GCAP2 affected guanylyl cyclase activity in two ways; (a) the maximal r

108 mouse GCAP2 produced similar effects on the guanylyl cyclase activity in wild type retinas.

109 The guanylyl cyclase activity is modulated by the calcium-bi

110 xposed to green light, whereas inhibition of guanylyl cyclase activity negatively affects fungal phot

111 in 20 min, LH treatment results in decreased guanylyl cyclase activity of NPR2, as determined in the

112 Therefore, GCAP2 regulation of guanylyl cyclase activity quickens the recovery of flash

113 me activity, consistent with ATP stimulating guanylyl cyclase activity through an allosteric, phospho

114 y Ca(2+)-dependent binding of recoverin, (2) guanylyl cyclase activity via Ca(2+)-dependent GCAP prot

115 vity, DGK4 recombinant protein also revealed guanylyl cyclase activity, as inferred by sequence analy

116 CAP1 and GCAP2, confer Ca(2+) sensitivity to guanylyl cyclase activity, but the importance and the co

117 r catalytic spines within the PKDs increased guanylyl cyclase activity, increased sensitivity to natr

118 The protein exhibits robust light-dependent guanylyl cyclase activity, whereas a truncated form lack

119 eta1-sGC protein content, and impair soluble guanylyl cyclase activity.

120 igated how ATP binding to the PKD influenced guanylyl cyclase activity.

121 oso-N-acetyl-DL-penicillamine) and a soluble guanylyl cyclase agonist (YC-1) mimicked AMPA effect in

122 and GCalpha, a fusion protein composed of a guanylyl cyclase and a phospholipid transporter domain.

123 Although guanylyl cyclase and downstream cGMP are essential regul

124 cAMP receptor protein (CRP) is linked to the guanylyl cyclase and when deleted is deficient in cyst d

125 C-type natriuretic peptide activation of guanylyl cyclase B (GC-B), also known as natriuretic pep

126 ceptor for C-type natriuretic peptide (CNP), guanylyl cyclase B (GC-B, also known as Npr2 or NPR-B),

127 tor 3 and inactivating mutations in the NPR2 guanylyl cyclase both cause severe short stature, but ho

128 ependent vasodilation, which is dependent on guanylyl cyclase but not prostaglandins.

129 Blockade of soluble guanylyl cyclase by ODQ (1H-[1,2,4] oxadiazolo[4,3,-a]qu

130 Guanylyl cyclase C (GC-C) has been shown to be the prima

131 Guanylyl cyclase C (GC-C) is a multidomain, membrane-ass

132 Guanylyl cyclase C (GC-C) is expressed in intestinal epi

133 Guanylyl cyclase C (GC-C), the receptor for diarrheageni

134 rgeting the intestinal cancer mucosa antigen guanylyl cyclase C (GCC) and its effect on inflammatory

135 tems, and the bacterial enterotoxin receptor guanylyl cyclase C (GCC), the principle source of cGMP i

136 ic tumors all express a unique surface-bound guanylyl cyclase C (GCC), which binds the diarrheagenic

137 ylin and uroguanylin, endogenous ligands for guanylyl cyclase C (GCC).

138 nuation of the colonic cell surface receptor guanylyl cyclase C (GUCY2C) that occurs due to loss of i

139 Guanylyl cyclase C (GUCY2C), a membrane-bound guanylyl c

140 enovirus (Ad5) combination regimen targeting guanylyl cyclase C (GUCY2C), a receptor expressed by int

141 endogenous ligands for the tumor suppressor guanylyl cyclase C (GUCY2C), disrupting a network of hom

142 Conversely, activating guanylyl cyclase C in human colon cancer cells delayed c

143 of a type I (microbial) rhodopsin domain and guanylyl cyclase catalytic domain.

144 cretes cGMP when developing cysts and that a guanylyl cyclase deletion strain fails to synthesize cGM

145 levation of cGMP after activation of soluble guanylyl cyclase does not relax the muscle.

146 ion of the cyclase activity, we isolated the guanylyl cyclase domain from Escherichia coli with (GCwC

147 tivation of the C-terminal cGMP-synthesizing guanylyl cyclase domain.

148 , combining a type I rhodopsin domain with a guanylyl cyclase domain.

149 smembrane receptors containing intracellular guanylyl cyclase domains, such as GC-A and GC-B, also kn

150 uanylyl cyclase C (GUCY2C), a membrane-bound guanylyl cyclase expressed in intestinal epithelial cell

151 segment of a natriuretic peptide receptor A guanylyl cyclase failed to bind GCAPs, but replacing its

152 nsory neurons (OSNs) expressing the receptor guanylyl cyclase GC-D, the cyclic nucleotide-gated chann

153 After stimulation with nitric oxide, soluble guanylyl cyclase generates cGMP, which induces vasodilat

154 s alters expression of AFD-specific receptor guanylyl cyclase genes.

155 We find that the Drosophila receptor guanylyl cyclase Gyc76C genetically interacts with Semap

156 on by the ligand NPPC, NPR2, the predominant guanylyl cyclase in follicular somatic cells, produces c

157 nated BlgC, was found to have photoactivated guanylyl cyclase in vitro.

158 induced airway relaxation was resistant to a guanylyl cyclase inhibitor (ODQ) and a protein kinase G

159 -nitro-L-arginine methyl ester (L-NAME), the guanylyl cyclase inhibitor 1H- [1,2,4]oxadiazolo[4,3-a]q

160 Porcine leaflets exposed to the soluble guanylyl cyclase inhibitor ODQ increased osteocalcin and

161 mediated depolarizations were blocked by the guanylyl cyclase inhibitor ODQ indicating involvement of

162 nt with either a Ca(2+) channel blocker or a guanylyl cyclase inhibitor.

163 In addition to L-NAME, the guanylyl cyclase inhibitors ODQ and thrombospondin-1 als

164 Ps(-/-)) rods, indicating that regulation of guanylyl cyclase is not necessary for at least a part of

165 In cones, calcium feedback to guanylyl cyclase is potentially a key step in phototrans

166 lation of cGMP synthesis by retinal membrane guanylyl cyclase isozymes (RetGC1 and RetGC2) in rod and

167 nthesis in photoreceptor by retinal membrane guanylyl cyclase isozymes (RetGC1 and RetGC2) to expedit

168 ice that lack NO-GC specifically in SMCs (SM-guanylyl cyclase knockout [GCKO]), ICCs (ICC-GCKO), or b

169 in the granulosa cells by the transmembrane guanylyl cyclase natriuretic peptide receptor 2 (NPR2) i

170 natriuretic peptide (CNP), its receptor, the guanylyl cyclase natriuretic peptide receptor 2 (Npr2),

171 granulosa cells, where it is produced by the guanylyl cyclase natriuretic peptide receptor 2 (NPR2).

172 ow that one of these molecules, the receptor guanylyl cyclase Npr2, is required for bifurcation of th

173 hermore, inhibition of the NO target soluble guanylyl cyclase or of the cGMP effector kinase protein

174 Inhibitors of soluble guanylyl cyclase or PKG decreased activity of the I425V

175 n suppressing Foxp3(+) Tregs via the soluble guanylyl cyclase pathway.

176 does not require the PI3 kinase/Akt/PKB and guanylyl cyclase pathways to induce chemorepulsion.

177 luding the insulin, TGF-beta, serotonin, and guanylyl cyclase pathways; however, the sensory processe

178 nic mutation carriers contained less soluble guanylyl cyclase protein and consequently displayed redu

179 hosphodiesterase 5 or stimulators of soluble guanylyl cyclase rapidly enhanced multiple proteasome ac

180 dly hypotensive and functions via a separate guanylyl cyclase receptor compared with CNP.

181 se (eNOS) by directly activating its soluble guanylyl cyclase receptor, rescued blood vessel function

182 the natural ligands for cell membrane-bound guanylyl cyclase receptors that mediate the effects of n

183 s, evolutionary diversification of primitive guanylyl cyclase signaling pathways allows GUCY2C to coo

184 chieved by activating the endogenous soluble guanylyl cyclase that produces cGMP.

185 at this toxin is a dual soluble adenylyl and guanylyl cyclase that results in intracellular cAMP and

186 olar concentrations of nitric oxide activate guanylyl cyclase to produce cGMP, which has diverse phys

187 its receptor on the intestinal brush border, guanylyl cyclase type C (GC-C).

188 es an effector domain such as an adenylyl or guanylyl cyclase, all encoded in a single protein as a t

189 cked by inhibitors of nitric oxide synthase, guanylyl cyclase, and calcium/calmodulin.

190 phosphorylation and inactivation of the NPR2 guanylyl cyclase, and cGMP hydrolysis is increased by ac

191 ing pathway involving nitric oxide synthase, guanylyl cyclase, and cGMP-dependent protein kinase (PKG

192 e roles of endothelium-derived vasodilators, guanylyl cyclase, and potassium channels were examined i

193 dependent, as well as nitric oxide (NO) and guanylyl cyclase, but not prostaglandin dependent.

194 gether with Ca(2+)-dependent acceleration of guanylyl cyclase, can successfully account for changes i

195 ugh H(2)S does not directly activate soluble guanylyl cyclase, it maintains a tonic inhibitory effect

196 ynthesis, L-NNA, and an inhibitor of soluble guanylyl cyclase, ODQ, greatly enhanced colonic contract

197 3-a]quinoxalon-1-one, a potent inhibitor for guanylyl cyclase, or 1,2-bis(2-aminophenoxy)ethane-N,N,N

198 that release nitric oxide, stimulate soluble guanylyl cyclase, or activate cGMP-dependent protein kin

199 all kingdoms of life, e.g. in human retinal guanylyl cyclase, our findings may be significant for ma

200 inhibitors of NO synthase (NOS) and soluble guanylyl cyclase, respectively, abolished tadalafil indu

201 5'-cyclic monophosphate ([cGMP]i) by soluble guanylyl cyclase, resulting in fast onset and long-lasti

202 xide that retrogradely activated presynaptic guanylyl cyclase, resulting in the presynaptic expressio

203 +) in its EF-hands, stimulates photoreceptor guanylyl cyclase, RetGC1, in response to light.

204 To convert BlaC into a guanylyl cyclase, we constructed a model of the nucleoti

205 tion of NO species and activation of soluble guanylyl cyclase, where xanthine oxidoreductase is propo

206 yclase, which synthesizes cGMP, or a mutated guanylyl cyclase, which synthesizes cAMP.

207 e conditional expression of either wild-type guanylyl cyclase, which synthesizes cGMP, or a mutated g

208 Signaling is both soluble guanylyl cyclase- and phosphodiesterase 6-dependent but

209 ated enzymes, adenylyl cyclase-5 and retinal guanylyl cyclase-1.

210 Atrial natriuretic peptide (ANP) binds guanylyl cyclase-A (GC-A) and natriuretic peptide recept

211 t was shown that NPs, via their cGMP-forming guanylyl cyclase-A (GC-A) receptor and cGMP-dependent ki

212 Atrial natriuretic peptide (ANP) via its guanylyl cyclase-A (GC-A) receptor participates in regul

213 Guanylyl cyclase-A (GC-A) signaling, a natriuretic pepti

214 rtension decreases urine output, and second, guanylyl cyclase-A (GC-A), the primary signaling recepto

215 Guanylyl cyclase-A (GC-A), the transmembrane cGMP-produc

216 with endothelial-restricted deletion of the guanylyl cyclase-A receptor for ANP.

217 HF serums were active and generated cGMP via guanylyl cyclase-A receptors; however, the 180-minute sa

218 Atrial natriuretic peptide (ANP) binds guanylyl cyclase-A/natriuretic peptide receptor-A (GC-A/

219 9C or E155G mutations of the retGC modulator guanylyl cyclase-activating protein 1 (GCAP-1), which pr

220 Guanylyl cyclase-activating protein 1 (GCAP1), a myristo

221 ackground light; similar effects are seen in guanylyl cyclase-activating protein knockout (GCAPs(-/-)

222 The guanylyl cyclase-activating protein, GCAP1, activates ph

223 clase (RetGC) activation via calcium-sensing guanylyl cyclase-activating proteins (GCAP), and RD3 tru

224 The photoreceptor-specific proteins guanylyl cyclase-activating proteins (GCAPs) bind and re

225 ane guanylyl cyclase 1 (RetGC1) regulated by guanylyl cyclase-activating proteins (GCAPs) controls ph

226 eceptors from degeneration by competing with guanylyl cyclase-activating proteins (GCAPs), which are

227 r segment and suppresses RetGC activation by guanylyl cyclase-activating proteins (GCAPs).

228 RetGC catalytic activity and stimulation by guanylyl cyclase-activating proteins (GCAPs).

229 structure of human BNP to activate GC-A and guanylyl cyclase-B (GC-B), which is not reduced in heart

230 g 8-bromo-cGMP, as well as by the NO-soluble guanylyl cyclase-cGMP signaling inhibitor thrombospondin

231 ts in target cells by binding to specialized guanylyl cyclase-coupled receptors, resulting in cGMP ge

232 rough which NO generally acts is the soluble guanylyl cyclase-cyclic GMP (sGC-cGMP) pathway.

233 Activation of the guanylyl cyclase-cyclic GMP-protein-kinase-G system with

234 adiazolo-[4,3-a]quinoxalin-1-one) (a soluble guanylyl cyclase-inhibitor, Rp-8-(4-chlorophenylthio)-gu

235 NP is a critical discriminator of binding to guanylyl cyclase-linked but not clearance natriuretic pe

236 ndicating that NO-induced AMPK activation is guanylyl cyclase-mediated and calcium-dependent.

237 n of Foxp3 in MBP-primed T cells via soluble guanylyl cyclase-mediated production of cGMP.

238 extent, by the direct stimulation of soluble guanylyl cyclase.

239 a multidomain, membrane-associated receptor guanylyl cyclase.

240 h, among other functions, stabilizes soluble guanylyl cyclase.

241 but not natriuretic peptide (NP)-stimulated guanylyl cyclase.

242 ion of a competitive inhibitor of a receptor guanylyl cyclase.

243 vitro, demonstrating that it is a functional guanylyl cyclase.

244 ssion of NF-kappaB and activation of soluble guanylyl cyclase.

245 ein-coupled receptors, adenylyl cyclase, and guanylyl cyclase.

246 f cGMP in response to nitric oxide-activated guanylyl cyclase.

247 way and the subsequent activation of soluble guanylyl cyclase.

248 ndothelial nitric-oxide synthase and soluble guanylyl cyclase.

249 the hsp90 chaperone machinery and by soluble guanylyl cyclase.

250 ndothelial nitric oxide synthase and soluble guanylyl cyclase.

251 The nitric oxide-sensitive guanylyl cyclase/cGMP-dependent protein kinase type I si

252 hyperphosphorylation occurs through soluble guanylyl cyclase/guanosine 3',5'-cyclic monophosphate si

253 rial and brain natriuretic peptides activate guanylyl cyclase/natriuretic peptide receptor-A (GC-A/NP

254 ibrosis and dysfunction using Npr1 (encoding guanylyl cyclase/natriuretic peptide receptor-A, GC-A/NP

255 tion of retinal arterioles via activation of guanylyl cyclase; cyclooxygenase plays a relatively mino

256 her the classical, nitric oxide (NO)-soluble guanylyl-cyclase (sGC)-cGMP pathway could modulate Ca(2)

257 rect inhibitors of an NRE-localized receptor-guanylyl-cyclase, GCY-8, which synthesizes cyclic guanos

258 The effect of CORM-2 was not prevented by guanylyl-cyclase, protein kinase G, or thioredoxin inhib

259 n modification, biologically through soluble guanylyl-cyclase-dependent modulation of the MMP-9/TIMP-

260 e identified a link between impaired soluble-guanylyl-cyclase-dependent nitric oxide signalling and m

261 eight different receptor-type, transmembrane guanylyl cyclases (encoded by gcy genes), which are expr

262 Guanylyl cyclases (GCs) catalyze the conversion of GTP t

263 ions of phosphodiesterase (PDE6) and retinal guanylyl cyclases (GCs), and mutations in genes that dis

264 uses PAK to directly activate transmembrane guanylyl cyclases (GCs), leading to increased cellular c

265 Guanylyl cyclases (GCs), which synthesize the messenger

266 to the activation of receptor enzymes called guanylyl cyclases (GCs).

267 expression levels of particulate (membrane) guanylyl cyclases (pGC) and cGMP-specific phosphodiester

268 or repertoire of cilia-localized particulate guanylyl cyclases (pGC-G and pGC-A).

269 We show that AFD-specific receptor guanylyl cyclases (rGCs) are instructive for thermosensa

270 the observation that multiple receptor-type guanylyl cyclases (rGCs), encoded by the gcy genes, and

271 total of 27 gcy genes encoding receptor-type guanylyl cyclases and of 7 gcy genes encoding soluble gu

272 erotrimeric G proteins but is independent of guanylyl cyclases and the previously identified cGMP-ind

273 s issue, report direct communication between guanylyl cyclases and the Rac-p21-activated kinase (PAK)

274 s, harbors a catalytic center diagnostic for guanylyl cyclases and the recombinant AtPNP-R1 is capabl

275 dely distributed across all kingdoms whereas guanylyl cyclases are generally thought to be restricted

276 l motility, through allosteric activation of guanylyl cyclases by autophosphorylated PAK.

277 ntrol of cGMP levels and that membrane-bound guanylyl cyclases can be critically modulated by other r

278 Although guanylyl cyclases have been implicated in cell migration

279 cyclases and of 7 gcy genes encoding soluble guanylyl cyclases in the complete genome sequence of C.

280 not using the PI3 kinase/Akt/PKB pathway and guanylyl cyclases, AprA does not induce actin polymeriza

281 g membrane-integral and soluble adenylyl and guanylyl cyclases, are central components in a wide rang

282 naling proteins, including eucaryal receptor guanylyl cyclases, but its function remains obscure.

283 The three Drosophila atypical soluble guanylyl cyclases, Gyc-89Da, Gyc-89Db, and Gyc-88E, have

284 BPIPP inhibited stimulation of guanylyl cyclases, including types A and B and soluble i

285 rs is supported by a pair of retina-specific guanylyl cyclases, retGC1 and -2.

286 canonical 5'-3' DNA polymerases and adenylyl/guanylyl cyclases, two enzyme families known to use a tw

287 te the catalytic activation of transmembrane guanylyl cyclases.

288 nfers Ca(2+)-dependent activation of retinal guanylyl cylcase (RetGC) during phototransduction in vis

289 Soluble guanylyl/guanylate cyclase (sGC) converts GTP to cGMP af

290 Soluble guanylyl/guanylate cyclase (sGC), a heme-containing hete

291 Soluble guanylyl/guanylate cyclase (sGC), the primary biological

292 pockets are occupied by the GTP analogue 5'-guanylyl imidodiphosphate and the next three by GDP, whi

293 e U5 region between Src homology 3 (SH3) and guanylyl kinase-like (GK) domains were identified in rat

294 miting enzyme required for the production of guanylyl metabolites and cGMP.

295 cial case of the model in which agonists and guanylyl nucleotides interact within a complex that is b

296 allosteric interaction between agonists and guanylyl nucleotides.

297 de-ion transport stimulated by activation of guanylyl or adenylyl cyclases and suppressed STa-induced

298 is, an open GTase domain for His217-mediated guanylyl transfer, and an open methylase-1 domain for SA

299 thway: (i) guanylylation of the enzyme, (ii) guanylyl-transfer to the RNA substrate, and (iii) overal

300 alent plant ICA genes encoding two tRNA(His) guanylyl transferase 1 units evolved ~120 million years